Propanamide, N-pentyl-

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Propanamide, N-pentyl-
• 英文别名: N-pentylpropanamide
• 化学式: C₈H₁₇NO
• mdl: MFCD03375983
• 分子量: 143.23
• InChiKey: IVHSRZSQMQJLKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS
  申请人：Pinto Donald J.P.

  公开号：US20100016316A1

  公开（公告）日：2010-01-21

  The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L 1 , R 3 , R 4 , R 8a , R 11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了化合物的结构式（I）或（II）： 或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式，其中变量A、L1、R3、R4、R8a、R11和M如本文所定义。结构式（I）或（II）的化合物是凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、Xa因子、XIa因子、IXa因子、VIIa因子和/或血浆激肽。具体而言，涉及选择性XIa因子抑制剂或fXIa和血浆激肽的双重抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• INHIBITING FATTY ACID SYNTHASE (FASN)
  申请人：Forma Therapeutics, Inc.

  公开号：EP3636637A1

  公开（公告）日：2020-04-15

  The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

  本公开涉及FASN的抑制剂。这些化合物可用于治疗与FASN抑制相关的疾病或疾病。例如，本公开涉及用于抑制FASN的化合物和组合物，治疗、预防或改善与FASN抑制相关的疾病或疾病的方法，以及这些化合物的合成方法。
• [EN] ADRENOMEDULLIN-ANALOGUES FOR LONG-TERM STABILIZATION AND THEIR USE<br/>[FR] ANALOGUES D'ADRÉNOMÉDULLINE POUR STABILISATION À LONG TERME ET LEUR UTILISATION
  申请人：BAYER AG

  公开号：WO2020254197A1

  公开（公告）日：2020-12-24

  The invention relates to stabilized Adrenomedullin derivatives and use thereof. In particular, the invention relates to novel, biologically active, stabilized Adrenomedullin (ADM) compounds. The invention further relates to the compounds for use in a method for the treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, and to medicaments comprising the compounds for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

  该发明涉及稳定的肾上腺髓质素衍生物及其用途。具体而言，该发明涉及新型、具有生物活性的稳定肾上腺髓质素（ADM）化合物。该发明进一步涉及用于治疗和/或预防疾病的方法中的化合物，特别是心血管、水肿和/或炎症性疾病，以及包含该化合物的药物，用于治疗和/或预防心血管、水肿和/或炎症性疾病。
• [EN] 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DÉRIVÉS DE 1-ARYL-PROPIONAMIDE UTILES COMME ANTAGONISTES DES RÉCEPTEURS DE LA BRADYKININE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：DOMPE SPA

  公开号：WO2011051375A1

  公开（公告）日：2011-05-05

  (R,S) 2-aryl-propionamide derivatives, or their single enantiomers (R) and (S) are disclosed useful in the treatment or prevention of symptoms and disorders such as pain and inflammation associated with the bradykinin B1 pathway.

  (R,S) 2-芳基丙酰胺衍生物，或其单对映体(R)和(S)，被披露用于治疗或预防与布雷金肽B1途径相关的症状和疾病，如疼痛和炎症。
• [EN] SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF<br/>[FR] LIGANDS DE COMPOSÉS DÉGRADANT DES RÉCEPTEURS D'ANDROGÈNES SÉLECTIFS (SARD) ET LEURS MÉTHODES D'UTILISATION
  申请人：GTX INC

  公开号：WO2016172330A1

  公开（公告）日：2016-10-27

  This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

  这项发明提供了新型的3-氨基丙酰胺选择性雄激素受体降解剂（SARD）化合物，以及在治疗前列腺癌、晚期前列腺癌、去势抵抗性前列腺癌、雄激素性脱发或其他高雄激素皮肤疾病、肯尼迪病、肌萎缩侧索硬化症（ALS）和子宫肌瘤中的应用的药物组合物，以及用于减少受试者中雄激素受体全长（AR-FL）包括致病性或耐药突变、AR剪接变体（AR-SV）和AR的致病性多谷氨酸（polyQ）多态性的水平的方法。